Lisa A. Damico‐Beyer

694 total citations
16 papers, 527 citations indexed

About

Lisa A. Damico‐Beyer is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Lisa A. Damico‐Beyer has authored 16 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in Lisa A. Damico‐Beyer's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Retinal Diseases and Treatments (3 papers). Lisa A. Damico‐Beyer is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Retinal Diseases and Treatments (3 papers). Lisa A. Damico‐Beyer collaborates with scholars based in United States, France and Switzerland. Lisa A. Damico‐Beyer's co-authors include Amita Joshi, Nelson L. ‘Shasha’ Jumbe, Steve Eppler, Lisa Tuomi, Tong Lu, Lu Xu, Jianfeng Lü, Peter Kuebler, Xin Yan and Shuang Bai and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Lisa A. Damico‐Beyer

16 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa A. Damico‐Beyer United States	10	259	199	164	141	134	16	527
David Fei United States	5	437 1.7×	341 1.7×	500 3.0×	82 0.6×	79 0.6×	7	839
Virginia Picasso Italy	12	29 0.1×	314 1.6×	157 1.0×	400 2.8×	197 1.5×	16	661
Janice Shipe-Spotloe United States	9	39 0.2×	245 1.2×	30 0.2×	368 2.6×	259 1.9×	16	547
Elena Tornari Italy	9	42 0.2×	161 0.8×	32 0.2×	244 1.7×	108 0.8×	12	431
Feiteng Lu China	12	27 0.1×	118 0.6×	21 0.1×	102 0.7×	63 0.5×	21	306
Molykutty John‐Aryankalayil United States	9	134 0.5×	201 1.0×	16 0.1×	104 0.7×	70 0.5×	10	413
L. Orgiano Italy	8	18 0.1×	180 0.9×	32 0.2×	226 1.6×	108 0.8×	13	382
Christine Longvert France	12	17 0.1×	233 1.2×	43 0.3×	353 2.5×	106 0.8×	34	525
Zongtai Zheng China	13	79 0.3×	233 1.2×	25 0.2×	97 0.7×	37 0.3×	37	504

Countries citing papers authored by Lisa A. Damico‐Beyer

Since Specialization

Citations

This map shows the geographic impact of Lisa A. Damico‐Beyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa A. Damico‐Beyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa A. Damico‐Beyer more than expected).

Fields of papers citing papers by Lisa A. Damico‐Beyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa A. Damico‐Beyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa A. Damico‐Beyer. The network helps show where Lisa A. Damico‐Beyer may publish in the future.

Co-authorship network of co-authors of Lisa A. Damico‐Beyer

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa A. Damico‐Beyer. A scholar is included among the top collaborators of Lisa A. Damico‐Beyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa A. Damico‐Beyer. Lisa A. Damico‐Beyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Le, Kha, Leonid Gibiansky, Menno van Lookeren Campagne, et al.. (2015). A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy. Journal of Pharmacology and Experimental Therapeutics. 355(2). 288–296. 24 indexed citations

2.

Kamath, Amrita V., Victor Yip, Priyanka Gupta, et al.. (2014). Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. mAbs. 6(6). 1631–1637. 15 indexed citations

3.

Huseni, Mahrukh, Klára Tótpál, Changchun Du, et al.. (2014). Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations

4.

Loyet, Kelly M., Xiangdan Wang, Jihong Yang, et al.. (2014). Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration. Journal of Pharmacology and Experimental Therapeutics. 351(3). 527–537. 40 indexed citations

5.

Huseni, Mahrukh, Klára Tótpál, Changchun Du, et al.. (2014). Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations

6.

Prell, Rodney A., Wendy Halpern, Joseph C. Beyer, et al.. (2014). 424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916. European Journal of Cancer. 50. 136–136. 1 indexed citations

7.

Xiang, Hong, Brendan C. Bender, Arthur E. Reyes, et al.. (2013). Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development. Clinical Cancer Research. 19(18). 5068–5078. 28 indexed citations

8.

Xu, Lu, Tong Lu, Lisa Tuomi, et al.. (2013). Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach. Investigative Ophthalmology & Visual Science. 54(3). 1616–1616. 161 indexed citations

9.

Xiang, Hong, Arthur E. Reyes, Steve Eppler, Sean K. Kelley, & Lisa A. Damico‐Beyer. (2013). Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection. Cancer Chemotherapy and Pharmacology. 72(2). 405–415. 8 indexed citations

10.

Yan, Xin, Stephen Eppler, Lisa A. Damico‐Beyer, et al.. (2013). Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. The Journal of Clinical Pharmacology. 53(11). 1103–1111. 33 indexed citations

11.

Kamath, Amrita V., Simon P. Williams, Sherry Bullens, et al.. (2012). Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to Oxidized LDL in Cynomolgus Monkey Using PET Imaging. PLoS ONE. 7(9). e45116–e45116. 3 indexed citations

12.

Yan, Xin, Shuang Bai, Lisa A. Damico‐Beyer, et al.. (2012). Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans. Pharmaceutical Research. 29(9). 2512–2521. 25 indexed citations

13.

Bai, Shuang, Karin Jorga, Xin Yan, et al.. (2012). A Guide to Rational Dosing of Monoclonal Antibodies. Clinical Pharmacokinetics. 51(2). 119–135. 127 indexed citations

14.

Yan, Xin, Hong Xiang, Frank‐Peter Theil, et al.. (2012). Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model. Journal of Pharmacokinetics and Pharmacodynamics. 39(2). 217–226. 7 indexed citations

15.

Kamath, Amrita V., Dan Lu, Priyanka Gupta, et al.. (2011). Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemotherapy and Pharmacology. 69(4). 1063–1069. 32 indexed citations

16.

Kamath, Amrita V., Dan Lu, Priyanka Gupta, et al.. (2011). Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Cancer Chemotherapy and Pharmacology. 69(4). 1071–1078. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact